Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. Alnylam’s pioneering work has delivered the world’s first and only approved RNAi therapeutics – Onpattro, Givlaari, and Oxlumo. Alnylam continues to advance a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Gilead Sciences, Inc., located in Foster City, CA, is a research-based biopharmaceutical company that is a leader in treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead’s portfolio of 15 marketed products includes a number of category firsts, including the only complete treatment regiments for HIV infection available in a once-daily single pill. Gilead’s portfolio also includes Truvada, the first drug approved for HIV prevention in uninfected adults at high risk.
Headquartered in Seal Beach, California, Dendreon Pharmaceuticals develops immunotherapies to treat cancer. Its flagship product, Provenge, was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 40,000 men with advanced prostate cancer have been treated with Provenge.
The Ambulatory Surgery Center Association represents more than 11,000 facilities and corporate ambulatory surgery centers (ASCs), which provide a less expensive and higher quality alternative for outpatient surgery than outpatient hospital departments.
Pediatrix Medical Group is a leading provider of specialized health care for women, babies and children in the United States. As a national physician-led medical group, Pediatrix delivers high-quality, evidence-based care across the entire care continuum. Through specialty-focused education, continuous quality improvement and safety initiatives, Pediatrix supports clinicians and hospitals in achieving better patient outcomes while reducing costs.
The American Occupational Therapy Association (AOTA) represents the interests and concerns of 230,000 occupational therapy practitioners and students. AOTA’s major programs and activities are directed toward assuring the quality of occupational therapy services, improving consumer access to healthcare services, and promoting the professional development of members.
Founded in 2008, The Large Urology Group Practice Association (LUPGA) represents independent urology physician practices that provide comprehensive and integrated urological care for patients with prostate cancer, bladder cancer, and other ailments.
The National Association of Freestanding Emergency Centers (NAFEC) represents the spectrum of FECs, including independent, hospital-owned, and hybrid models alike. They were established to advocate for fair regulation and to raise statewide awareness of freestanding emergency centers as a high-quality, accessible, emergency medical care option.
The Infusion Providers Alliance (IPA) is the leading voice for providers of drug infusion services in this outpatient setting of care and leads an effort to preserve the integrity of the doctor-patient relationship in a manner that delivers exceptional care to patients at a lower cost to the health care system. The IPA represents infusion providers with over 930 locations in more than 42 states across the U.S. Collectively, the IPA members administer more than 640,000 treatments annually.
Located in South San Francisco, Genentech is a leader in cancer care with treatments including Avastin, Actemra, Tacerva, Lucentis, Erivedge, PERJETA, and Kadcyla. Now owned by Roche Holdings, the company employs nearly 14,000 people.
EMD Serono, Inc. is a German-based company with more than 1,300 employees throughout the United States headquartered in Rockland, Massachusetts. With a deep expertise in neurology, fertility, and endocrinology, EMD Serono has a strong pipeline with more than 20 trials in their global clinical pipeline. Projects include potential new oncology and immuno-oncology medicines as well as therapeutic options for psoriasis, lupus, multiple sclerosis, and other autoimmune diseases.
Zimmer Biomet, headquartered in Warsaw, Indiana, is a global leader in musculoskeletal healthcare. They design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
Founded in 1992, The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, DC providing educational and advocacy assistance to more than 270 innovative and entrepreneurial medical technology companies. MDMA is the leading voice representing the interests of innovative and entrepreneurial medical technology companies.
Based in Menlo Park, CA, GRAIL is a clinical-stage diagnostics company developing a multi-cancer blood test for detection of more than 50 types of cancer across early and late stages. The test also aims to detect an individual’s cancer tissue of origin to guide physicians and patients toward a faster, more efficient, and most appropriate treatment.
At WEX Health, we simplify the business of healthcare. We do that through WEX Health Cloud, a cloud-based healthcare financial management platform that drives efficiency for benefit administration technology, consumer engagement, and advanced billing and payments. Our network of partner organizations enables us to deliver our industry-leading and award-winning solution to 343,000 employers and more than 28 million consumers across the United States, Canada, South America, Europe, Asia and Australia. Together we take the complexity out of defined contribution, HSAs, HRAs, FSAs, VEBAs, PRAs, premium billing, public and private health insurance exchanges, COBRA, wellness plans, and transit plans.
VIVEX develops and delivers innovative allografts designed to support the body’s healing potential to help improve patient outcomes and quality of life, who’s medical technologies date back 50 years to the founding of The University of Miami Tissue Bank in 1970. Since that time, VIVEX has distributed more than 2,000,000 allografts nationwide. VIVEX’s strategic plan focuses on the development of new innovative allografts, research and development, enhancement of manufacturing capabilities, and sales and marketing efforts.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents leading innovative and biopharmaceutical research companies in advancing public policies that support medical research, yield progress for patients, and provide hope for treatments and cures. Headquartered in Washington, D.C., PhRMA has nine locations in the United States and two international offices. Some of PhRMA’s member companies include Merck, Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, and Pfizer.
A member of the Roche Group, Roche Diagnostics’ headquarters, including its primary manufacturing site and distribution center, is located in Indianapolis, Indiana. Roche Diagnostics develops and produces digital tools and medical tests, leading the industry in developing diagnostic products for cancer, cardiac health, infectious diseases, diabetes management, and women’s health. Employing over 7,000 people, Roche Diagnostics’ experts engage in cutting-edge research and development, laboratory, manufacturing, distribution, information technology, and administrative operations.
Fulcrum Therapeutics is a clinical-stage biopharma company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need.
Acesso Biologics specializes in providing innovative wound care therapies and accessible skin substitutes to improve patient outcomes. Acesso Biologics collaborates with healthcare providers and industry leaders to deliver high-quality solutions that meet the diverse needs of patients with chronic and acute wounds.
BioWound Solutions’ mission is to change the dynamics of advanced wound care by providing healthcare practitioners with a wide range of solutions designed to promote healing and prevent complications such as amputations and infections. The BioWound portfolio includes technologies from multiple sources. When not owned directly, partnerships are formed with companies to bring their innovations to healthcare providers, helping them achieve full wound closure for patients.
Ardelyx® is dedicated to transforming patient care by developing innovative, first-in-class medicines that address significant unmet medical needs. Utilizing a unique discovery model, Ardelyx has identified new biological mechanisms to drive the development of targeted therapies. Through a combination of proprietary research and strategic partnerships, Ardelyx delivers breakthrough treatments to improve patient outcomes and advance the standard of care.